- Home
- CATX
as 09-18-2025 10:31am EST
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 239.0M | IPO Year: | N/A |
| Target Price: | $12.90 | AVG Volume (30 days): | 696.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $14.19 | Next Earning Date: | 11-11-2025 |
| Revenue: | $1,235,000 | Revenue Growth: | -15.64% |
| Revenue Growth (this year): | -22.08% | Revenue Growth (next year): | -31.57% |
Latest Perspective Therapeutics Inc. News
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
MT Newswires
3 months ago
B. Riley Raises Price Target on Perspective Therapeutics to $12 From $9, Keeps Buy Rating
GlobeNewswire
3 months ago
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
![Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial](/cdn/transform/width=500,quality=90,format=webp/https://cdn.finquota.com/news/648ddb0b-edd5-4b92-984f-05aca1853e6d.jpg)
GlobeNewswire
3 months ago
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
Simply Wall St.
3 months ago
3 Promising Penny Stocks With Market Caps Over $90M
MT Newswires
3 months ago
RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk
![Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting](/cdn/transform/width=500,quality=90,format=webp/https://cdn.finquota.com/news/3da3b33c-1825-4c9d-a123-3916a82f077a.jpg)
GlobeNewswire
4 months ago
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
Insider Monkey
4 months ago
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential
Compare CATX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CATX Perspective Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.